论文部分内容阅读
目的探索依达拉奉针剂在脑梗塞急性期应用过程中的疗效和不良反应。方法将171例脑梗死急性期的住院患者,随机分为两组,治疗组84例,常规组87例;治疗组在脑梗死急性期的常规治疗基础上加用依达拉奉针剂30mg;分别在治疗前和治疗后21d评估其神经功能缺损评分(NIHSS),及不良反应的发生情况。结果治疗组总有效率明显高于常规组,两者差异有统计学意义(P<0.05)。依达拉奉治疗第21d神经功能缺损的改善优于常规组(P<0.05)。依达拉奉治疗组4例(7.76%)出现不良反应。主要表现为皮疹1例(1.19%),肝功能轻微损害3例(3.57%),停药后症状消失或自行恢复正常。结论依达拉奉治疗急性脑梗塞临床疗效显著,能改善神经功能缺损,且安全性高。
Objective To explore the efficacy and adverse reactions of edaravone in the acute stage of cerebral infarction. Methods A total of 171 hospitalized acute cerebral infarction patients were randomly divided into two groups: 84 cases in the treatment group and 87 cases in the conventional group. The treatment group was treated with 30 mg of edaravone on the basis of routine treatment of acute cerebral infarction. The neurological deficit score (NIHSS) and the incidence of adverse reactions were evaluated before and 21 days after treatment. Results The total effective rate of the treatment group was significantly higher than that of the conventional group, the difference was statistically significant (P <0.05). Edaravone treatment at 21d improved neurological deficit better than the conventional group (P <0.05). Adalimuron treatment group 4 patients (7.76%) adverse reactions. Mainly as a rash in 1 case (1.19%), mild liver damage in 3 cases (3.57%), after stopping the symptoms disappear or self-recovery to normal. Conclusion Edaravone has a significant clinical effect in treating acute cerebral infarction. It can improve neurological deficits and is safe.